ArticleBrain and behavior2025
Multi-Omics Mendelian Randomization Identifies a DNA Methylation-ZDHHC20-Immune Axis Associated With Schizophrenia Risk.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neuronal Cell-Specific sc-eQTL and Integrative eQTL-pQTL Mendelian Randomization Prioritize CKAP2 as a Candidate Gene for Major Depressive Disorder.Journal of molecular neuroscience : MN · 2026Observational
- Transcriptomic Analysis and Multiple Machine Learning Approaches Identify ZDHHC20 and Its Highly Correlated Gene AK5 as Biomarkers in Multiple System Atrophy.Journal of molecular neuroscience : MN · 2026Article
- Multi-Omics Mendelian Randomization Identifies a DNA Methylation-ZDHHC20-Immune Axis Associated With Schizophrenia Risk.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is a severe psychiatric disorder with a complex etiology involving genetic and environmental factors. Despite its profound impact, the molecular mechanisms underlying schizophrenia remain elusive. Emerging evidence suggests that DNA methylation, palmitoylation, and immune cell activity play critical roles in its pathogenesis. This study employs a multi-omics approach to investigate the causal relationships among these factors and schizophrenia.
methodsWe utilized Mendelian randomization (MR), integrating expression, protein, and methylation quantitative trait loci (eQTL, pQTL, mQTL) to explore causal pathways in schizophrenia. Our approach involved (1) identifying palmitoylation-related genes and assessing their causal effects on schizophrenia via two-sample MR, validated by summary-data-based MR (SMR); (2) conducting mediation MR to examine upstream DNA methylation's role in gene regulation and its impact on schizophrenia; and (3) investigating downstream immune cell traits as mediators of gene effects on schizophrenia risk. Sensitivity analyses ensured robustness.
resultsWe found a significant causal association between increased ZDHHC20 expression, a palmitoyltransferase, and elevated schizophrenia risk (p < 0.05), confirmed by SMR. Upstream, DNA methylation at cg18095732 regulates ZDHHC20, mediating 59.31% of its effect on schizophrenia (p < 0.05). Downstream, CCR7 expression on naive CD8+ T cells mediates 33.35% of ZDHHC20's influence on schizophrenia risk (p < 0.05).
conclusionsThis study reveals a novel mechanistic axis in schizophrenia: DNA methylation-ZDHHC20-immune regulation, linking epigenetic modifications and palmitoylation to neuroimmune dysregulation. ZDHHC20 emerges as a potential therapeutic target, highlighting the value of multi-omics in psychiatric disease research and suggesting avenues for targeted interventions addressing both neuronal and immune contributions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.